Iovance (IOVA) | Financial Analysis & Statements
Iovance Biotherapeutics, Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
86.8M
Gross Profit
43.7M
50.32%
Operating Income
-73.5M
-84.66%
Net Income
-71.9M
-82.87%
Balance Sheet Metrics
Total Assets
913.2M
Total Liabilities
214.6M
Shareholders Equity
698.6M
Debt to Equity
0.31
Cash Flow Metrics
Operating Cash Flow
-75.1M
Free Cash Flow
-61.9M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Iovance Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 263.5M | 164.1M | 1.2M | 0 | 0 |
| Cost of Goods Sold | 173.2M | 124.0M | 10.8M | 0 | 0 |
| Gross Profit | 90.3M | 40.1M | -9.6M | 0 | 0 |
| Gross Margin % | 34.3% | 24.4% | -804.5% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 300.3M | 282.3M | 344.1M | 294.8M | 259.0M |
| Selling, General & Administrative | 152.3M | 153.0M | 106.9M | 104.1M | 83.7M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 452.6M | 435.4M | 451.0M | 398.9M | 342.7M |
| Operating Income | -398.2M | -395.3M | -460.6M | -398.9M | -342.7M |
| Operating Margin % | -151.1% | -240.9% | -38,735.0% | 0.0% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | 10.3M | 20.3M | 13.0M | 3.0M | 451.0K |
| Interest Expense | - | - | - | - | - |
| Other Non-Operating Income | -5.1M | - | - | - | - |
| Pre-tax Income | -393.0M | -375.0M | -447.5M | -395.9M | -342.3M |
| Income Tax | -2.1M | -2.8M | -3.5M | 0 | 0 |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -391.0M | -372.2M | -444.0M | -395.9M | -342.3M |
| Net Margin % | -148.4% | -226.8% | -37,345.4% | 0.0% | 0.0% |
| Key Metrics | |||||
| EBITDA | -345.7M | -351.7M | -427.4M | -377.7M | -328.7M |
| EPS (Basic) | $-1.09 | $-1.28 | $-1.89 | $-2.49 | $-2.23 |
| EPS (Diluted) | $-1.09 | $-1.28 | $-1.89 | $-2.49 | $-2.23 |
| Basic Shares Outstanding | 357345000 | 289877000 | 235131000 | 159259000 | 153406000 |
| Diluted Shares Outstanding | 357345000 | 289877000 | 235131000 | 159259000 | 153406000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Iovance Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 163.1M | 115.7M | 114.9M | 231.7M | 78.2M |
| Short-term Investments | 133.9M | 208.1M | 165.0M | 240.1M | 426.2M |
| Accounts Receivable | 82.4M | 69.3M | 151.0K | 0 | - |
| Inventory | 51.7M | 51.5M | 10.4M | 0 | - |
| Other Current Assets | 11.6M | 12.4M | 17.5M | 7.3M | 3.5M |
| Total Current Assets | 442.7M | 457.0M | 307.8M | 479.1M | 508.0M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 84.7M | 86.7M | 91.6M | 101.1M | 81.8M |
| Goodwill | 279.3M | 282.4M | 229.3M | 0 | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 14.1M | 6.7M | 66.7M | 6.6M | 7.9M |
| Total Non-Current Assets | 470.5M | 453.4M | 472.5M | 184.9M | 269.4M |
| Total Assets | 913.2M | 910.4M | 780.4M | 664.0M | 777.3M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 22.2M | 27.5M | 33.1M | 26.6M | 27.4M |
| Short-term Debt | 5.0M | 12.9M | 7.8M | 12.6M | 5.1M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 138.4M | 122.3M | 110.3M | 91.5M | 89.2M |
| Non-Current Liabilities | |||||
| Long-term Debt | 44.4M | 45.4M | 68.1M | 72.9M | 66.5M |
| Deferred Tax Liabilities | 31.8M | 32.3M | 17.3M | 0 | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 76.2M | 77.7M | 85.4M | 72.9M | 66.5M |
| Total Liabilities | 214.6M | 200.0M | 195.7M | 164.3M | 155.7M |
| Equity | |||||
| Common Stock | 17.0K | 13.0K | 11.0K | 8.0K | 7.0K |
| Retained Earnings | -2.8B | -2.4B | -2.0B | -1.6B | -1.2B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 698.6M | 710.4M | 584.6M | 499.6M | 621.7M |
| Key Metrics | |||||
| Total Debt | 49.4M | 58.3M | 75.9M | 85.4M | 71.5M |
| Working Capital | 304.3M | 334.7M | 197.5M | 387.6M | 418.8M |
Balance Sheet Composition
Iovance Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -391.0M | -372.2M | -444.0M | -395.9M | -342.3M |
| Depreciation & Amortization | 47.3M | 43.6M | 33.1M | 21.1M | 14.0M |
| Stock-Based Compensation | 61.6M | 109.6M | 62.6M | 84.0M | 69.8M |
| Working Capital Changes | -44.9M | -129.0M | -16.2M | 3.9M | 1.1M |
| Operating Cash Flow | -329.0M | -350.8M | -368.0M | -286.8M | -257.4M |
| Investing Activities | |||||
| Capital Expenditures | -33.8M | -11.1M | -22.3M | -20.4M | -37.6M |
| Acquisitions | 0 | -52.6M | -212.6M | 0 | 0 |
| Investment Purchases | -318.7M | -460.8M | -205.9M | -245.8M | -725.2M |
| Investment Sales | 400.0M | 428.0M | 285.6M | 522.7M | 762.9M |
| Investing Cash Flow | 47.5M | -96.4M | -155.2M | 256.5M | 132.0K |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | 0 | 0 | 1.0M |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 299.2M | 384.4M | 460.5M | 186.9M | 204.2M |
| Free Cash Flow | -336.2M | -364.0M | -384.1M | -313.2M | -265.5M |
| Net Change in Cash | 17.7M | -62.8M | -62.8M | 156.5M | -53.1M |
Cash Flow Trend
Iovance Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-3.19
Forward P/E
-15.63
Price to Book
2.18
Price to Sales
5.78
PEG Ratio
0.10
Profitability Ratios
Profit Margin
-148.38%
Operating Margin
-84.66%
Return on Equity
-55.50%
Return on Assets
-27.30%
Financial Health
Current Ratio
3.20
Debt to Equity
7.08
Beta
0.76
Per Share Data
EPS (TTM)
$-1.09
Book Value per Share
$1.70
Revenue per Share
$0.74
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| IOVA | 1.4B | -3.19 | 2.18 | -55.50% | -148.38% | 7.08 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Recursion | 1.9B | -2.44 | 1.64 | -59.54% | 4.45% | 6.89 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
Financial data is updated regularly. All figures are in the company's reporting currency.






